Assignee
ACTELION PHARMACEUTICALS LTD
CH·113 granted patents·52 pending applications·672 citations·filing 2000–2024
Top patents by PatentIndex Score
165 records- 0195US7875726B2Thiazolidin-4-one derivativesACTELION PHARMACEUTICALS LTD·Filed 2008·Granted Jan 25, 2011·24 cites·7 claims
- 0294US10220023B2Dosing regimen for a selective S1P1 receptor agonistACTELION PHARMACEUTICALS LTD·Filed 2015·Granted Mar 5, 2019·19 cites·12 claims
- 0394US7763638B2Substituted 1,2,3,4-tetrahydroisoquinoline derivativesACTELION PHARMACEUTICALS LTD·Filed 2005·Granted Jul 27, 2010·24 cites·6 claims
- 0494US7626037B2Thiazolidin-4-one derivativesACTELION PHARMACEUTICALS LTD·Filed 2008·Granted Dec 1, 2009·24 cites·24 claims
- 0594US7285549B2Sulfamides and their use as endothelin receptor antagonistsACTELION PHARMACEUTICALS LTD·Filed 2006·Granted Oct 23, 2007·27 cites·5 claims
- 0693US9173881B2Therapeutic compositions containing macitentanACTELION PHARMACEUTICALS LTD·Filed 2014·Granted Nov 3, 2015·8 cites·19 claims
- 0793USRE45174EThiazolidin-4-one derivativesACTELION PHARMACEUTICALS LTD·Filed 2013·Granted Sep 30, 2014·14 cites·8 claims
- 0892US9000018B2Thiazolidin-4-one-derivativesACTELION PHARMACEUTICALS LTD·Filed 2013·Granted Apr 7, 2015·13 cites·21 claims
- 0992US7994336B2Azetidine compounds as orexin receptor antagonistsACTELION PHARMACEUTICALS LTD·Filed 2007·Granted Aug 9, 2011·23 cites·15 claims
- 1092US7435828B2Thiazolidin-4-one derivativesACTELION PHARMACEUTICALS LTD·Filed 2004·Granted Oct 14, 2008·33 cites·27 claims
- 1191US11672783B2Pharmaceutical combination comprising a selective S1P1 receptor agonistACTELION PHARMACEUTICALS LTD·Filed 2021·Granted Jun 13, 2023·2 cites·15 claims
- 1291US11234980B2Pharmaceutical composition for the treatment of pulmonary arterial hypertensionACTELION PHARMACEUTICALS LTD·Filed 2021·Granted Feb 1, 2022·9 cites·30 claims
- 1391US8367685B2Stable pharmaceutical compositions comprising a pyrimidine-sulfamideACTELION PHARMACEUTICALS LTD·Filed 2009·Granted Feb 5, 2013·19 cites·16 claims
- 1491US7094781B2Sulfamides and their use as endothelin receptor antagonistsACTELION PHARMACEUTICALS LTD·Filed 2001·Granted Aug 22, 2006·38 cites·11 claims
- 1590US9597331B2Therapeutic compositions containing macitentanACTELION PHARMACEUTICALS LTD·Filed 2015·Granted Mar 21, 2017·3 cites·13 claims
- 1690US8003800B2Thiophene derivatives as S1P1/EDG1 receptor agonistsACTELION PHARMACEUTICALS LTD·Filed 2007·Granted Aug 23, 2011·18 cites·29 claims
- 1790US7750040B2Thiophene derivativesACTELION PHARMACEUTICALS LTD·Filed 2005·Granted Jul 6, 2010·17 cites·16 claims
- 1890US7723378B2Hydrogenated benzo (C) thiophene derivatives as immunomodulatorsACTELION PHARMACEUTICALS LTD·Filed 2006·Granted May 25, 2010·16 cites·20 claims
- 1989US11464777B2Pharmaceutical composition for the treatment of pulmonary arterial hypertensionACTELION PHARMACEUTICALS LTD·Filed 2021·Granted Oct 11, 2022·3 cites·23 claims
- 2089US10946015B2Stable pharmaceutical compositions comprising a pyrimidine-sulfamideACTELION PHARMACEUTICALS LTD·Filed 2018·Granted Mar 16, 2021·3 cites·42 claims
- 2189US7605269B2Thiophene derivatives as Sphingosine-1-phosphate-1 receptor agonistsACTELION PHARMACEUTICALS LTD·Filed 2006·Granted Oct 20, 2009·15 cites·17 claims
- 2288US10245253B2Pharmaceutical combination comprising a selective S1P1 receptor agonistACTELION PHARMACEUTICALS LTD·Filed 2015·Granted Apr 2, 2019·6 cites·12 claims
- 2388US8044076B2Phenyl derivatives and their use as immunomodulatorsACTELION PHARMACEUTICALS LTD·Filed 2007·Granted Oct 25, 2011·13 cites·19 claims
- 2488US7435815B2Sulfonylamino-acetic acid derivativesACTELION PHARMACEUTICALS LTD·Filed 2007·Granted Oct 14, 2008·10 cites·14 claims
- 2587US11026927B2Pharmaceutical combination comprising a selective S1P1 receptor agonistACTELION PHARMACEUTICALS LTD·Filed 2019·Granted Jun 8, 2021·4 cites·13 claims
- 2687US10653846B2Dosing apparatus for dispensing a fluid under aseptic conditionsACTELION PHARMACEUTICALS LTD·Filed 2016·Granted May 19, 2020·11 cites·12 claims
- 2787US9265762B2Stable pharmaceutical compositions comprising a pyrimidine-sulfamideACTELION PHARMACEUTICALS LTD·Filed 2013·Granted Feb 23, 2016·9 cites·16 claims
- 2886US8349828B2Azatricyclic antibiotic compoundsACTELION PHARMACEUTICALS LTD·Filed 2009·Granted Jan 8, 2013·5 cites·22 claims
- 2986US7834028B2Pyrazolo-tetrahydro pyridine derivatives as orexin receptor antagonistsACTELION PHARMACEUTICALS LTD·Filed 2007·Granted Nov 16, 2010·9 cites·19 claims
- 3085US7981924B2Thiophene derivativesACTELION PHARMACEUTICALS LTD·Filed 2006·Granted Jul 19, 2011·8 cites·34 claims
- 3185US2024131009A1Pharmaceutical combination comprising a selective s1p1 receptor agonistACTELION PHARMACEUTICALS LTD·Filed 2024·Application pending·0 cites
- 3284US9340518B2Process for the preparation of (2Z,5Z)-5-(3-chloro-4-((R)-2,3-dihydroxypropdxy)benzylidene)-2-(propylimino)-3-(o-tolyl)thiazolidin-4-one and intermediate used in said processACTELION PHARMACEUTICALS LTD·Filed 2013·Granted May 17, 2016·17 cites·18 claims
- 3384US8048881B2Pyrimidine derivatives and their use as P2Y12 receptor antagonistsACTELION PHARMACEUTICALS LTD·Filed 2006·Granted Nov 1, 2011·9 cites·16 claims
- 3484US8003654B2N-glycinsulfonamide derivatives and uses as orexin receptor antagonistsACTELION PHARMACEUTICALS LTD·Filed 2007·Granted Aug 23, 2011·7 cites·12 claims
- 3584US7951794B2Thiophene derivativesACTELION PHARMACEUTICALS LTD·Filed 2006·Granted May 31, 2011·9 cites·16 claims
- 3684US7846964B2Thiophene derivatives as spingosine-1-phosphate-1 receptor agonistsACTELION PHARMACEUTICALS LTD·Filed 2006·Granted Dec 7, 2010·11 cites·22 claims
- 3783US9211279B2Proline sulfonamide derivatives as orexin receptor antagonistsACTELION PHARMACEUTICALS LTD·Filed 2015·Granted Dec 15, 2015·3 cites·30 claims
- 3883US7714132B2Tetrahydropyridoindole derivativesACTELION PHARMACEUTICALS LTD·Filed 2005·Granted May 11, 2010·7 cites·25 claims
- 3982US10117870B2Stable pharmaceutical compositions comprising a pyrimidine-sulfamideACTELION PHARMACEUTICALS LTD·Filed 2016·Granted Nov 6, 2018·3 cites·20 claims
- 4082US9493446B2Orexin receptor antagonists which are [ortho bi-(hetero-)aryl]-[2-(meta bi-(hetero-)aryl)-pyrrolidin-1-yl]-methanone derivativesACTELION PHARMACEUTICALS LTD·Filed 2013·Granted Nov 15, 2016·6 cites·21 claims
- 4182US6703392B21,2,3,4-tetrahydroisoquinoline derivativesACTELION PHARMACEUTICALS LTD·Filed 2001·Granted Mar 9, 2004·20 cites·22 claims
- 4281US8664278B2Stabilized compositions of volatile alkylating agents and methods of using thereofACTELION PHARMACEUTICALS LTD·Filed 2013·Granted Mar 4, 2014·3 cites·23 claims
- 4381US8044055B22-phenyl-6-aminocarbonyl-pyrimidine derivatives and their use as P2Y12 receptorACTELION PHARMACEUTICALS LTD·Filed 2007·Granted Oct 25, 2011·5 cites·12 claims
- 4481US7868012B2Sulfamides as endothelin receptor antagonists for the treatment of cardiovascular diseasesACTELION PHARMACEUTICALS LTD·Filed 2005·Granted Jan 11, 2011·4 cites·13 claims
- 4580US10251867B2Dosing regimen for a selective S1P1 receptor agonistACTELION PHARMACEUTICALS LTD·Filed 2015·Granted Apr 9, 2019·2 cites·7 claims
- 4680US9617250B2Pyridin-4-yl derivativesACTELION PHARMACEUTICALS LTD·Filed 2014·Granted Apr 11, 2017·4 cites·11 claims
- 4780US7192950B2Benzazepines and related heterocyclic derivatives which are useful as orexin receptor antagonistsACTELION PHARMACEUTICALS LTD·Filed 2001·Granted Mar 20, 2007·15 cites·5 claims
- 4879US8039644B2Hydrogenated benzo (C) thiophene derivatives as immunomodulatorsACTELION PHARMACEUTICALS LTD·Filed 2010·Granted Oct 18, 2011·4 cites·20 claims
- 4979US7279578B2Sulfonylamino-acetic acid derivativesACTELION PHARMACEUTICALS LTD·Filed 2003·Granted Oct 9, 2007·11 cites·14 claims
- 5078US7959945B2Dispersible bosentan tabletACTELION PHARMACEUTICALS LTD·Filed 2006·Granted Jun 14, 2011·4 cites·3 claims
Showing the top 50 of 165 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when ACTELION PHARMACEUTICALS LTD files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →